202.97
-1.27(-0.62%)
Currency In USD
| Previous Close | 204.24 |
| Open | 204.85 |
| Day High | 205.99 |
| Day Low | 198.37 |
| 52-Week High | 212.49 |
| 52-Week Low | 93.58 |
| Volume | 30,230.34 |
| Average Volume | 210,218 |
| Market Cap | 3.99B |
| PE | 89.41 |
| EPS | 2.27 |
| Moving Average 50 Days | 194.31 |
| Moving Average 200 Days | 165.63 |
| Change | -1.27 |
If you invested $1000 in Ligand Pharmaceuticals Incorporated (LGND) 10 years ago, it would be worth $3,255.24 as of March 04, 2026 at a share price of $202.97. Whereas If you bought $1000 worth of Ligand Pharmaceuticals Incorporated (LGND) shares 5 years ago, it would be worth $2,295.96 as of March 04, 2026 at a share price of $202.97.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
GlobeNewswire Inc.
Feb 12, 2026 12:00 PM GMT
JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. The company will hold a conf
Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 04, 2026 12:00 PM GMT
JUPITER, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a fireside chat at the Oppenhe
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance
GlobeNewswire Inc.
Dec 09, 2025 12:00 PM GMT
Introduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue growth over 2025, royalty revenue of $200 to $225 million, a 40% increase over 20251, and core adjusted earnings per diluted sha